for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cue Biopharma Inc

CUE.OQ

Latest Trade

8.75USD

Change

-0.07(-0.79%)

Volume

200,433

Today's Range

8.59

 - 

8.99

52 Week Range

4.16

 - 

9.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.82
Open
8.72
Volume
200,433
3M AVG Volume
1.92
Today's High
8.99
Today's Low
8.59
52 Week High
9.90
52 Week Low
4.16
Shares Out (MIL)
22.58
Market Cap (MIL)
199.18
Forward P/E
-4.50
Dividend (Yield %)
--

Latest Developments

More

Cue Biopharma Announces FDA Acceptance Of Ind For Lead Immuno-Oncology Candidate, Cue-101, In Treatment Of Hpv-Driven Cancers

Cue Biopharma - On April 30,Gary Schuman Resigned As Interim CFO

Peter Appel Reports Passive Stake Of 7.6 Pct In Cue Biopharma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cue Biopharma Inc

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

Industry

Biotechnology & Drugs

Contact Info

21 Erie St

+1.617.9492680

https://www.cuebiopharma.com/

Executive Leadership

Daniel R. Passeri

President, Chief Executive Officer

Kerri-Ann Millar

Principal Financial Officer

Rodolfo J Chaparro

Executive Vice President - Head of Immunology

Ronald D. Seidel

Executive Vice President - Head of Research and Development

Colin G Sandercock

Senior Vice President, General Counsel

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-1.940

2019(E)

-1.960
Price To Earnings (TTM)
--
Price To Sales (TTM)
90.35
Price To Book (MRQ)
9.27
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-112.82
Return on Equity (TTM)
-94.80

Latest News

BRIEF-Peter Appel Reports Passive Stake Of 7.6 Pct In Cue Biopharma

* PETER APPEL REPORTS A PASSIVE STAKE OF 7.6 PERCENT IN CUE BIOPHARMA INC AS OF DEC 27, 2017 - SEC FILING Source text: (http://bit.ly/2BWquxU) Further company coverage:

BRIEF-Mark Strome Reports 5.7 Pct Passive Stake In Cue Biopharma

* MARK STROME REPORTS A 5.7 PERCENT PASSIVE STAKE IN CUE BIOPHARMA INC AS OF DECEMBER 27, 2017- SEC FILING Source: (http://bit.ly/2AIDG48) Further company coverage:

BRIEF-Cue Biopharma sees IPO of up to 8 mln shares of its common stock priced at $7.50/shr

* CUE BIOPHARMA INC SEES IPO OF UP TO 8 MILLION SHARES OF ITS COMMON STOCK PRICED AT $7.50 PER SHARE - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up